SG11201506799RA - Oxabicyclo [2.2.2] acid gpr120 modulators - Google Patents

Oxabicyclo [2.2.2] acid gpr120 modulators

Info

Publication number
SG11201506799RA
SG11201506799RA SG11201506799RA SG11201506799RA SG11201506799RA SG 11201506799R A SG11201506799R A SG 11201506799RA SG 11201506799R A SG11201506799R A SG 11201506799RA SG 11201506799R A SG11201506799R A SG 11201506799RA SG 11201506799R A SG11201506799R A SG 11201506799RA
Authority
SG
Singapore
Prior art keywords
oxabicyclo
gpr120 modulators
acid
acid gpr120
modulators
Prior art date
Application number
SG11201506799RA
Inventor
Hao Zhang
Peter T W Cheng
Sean Chen
Shiwei Tao
Shung C Wu
Lidet A Negash
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of SG11201506799RA publication Critical patent/SG11201506799RA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
SG11201506799RA 2013-03-14 2014-03-13 Oxabicyclo [2.2.2] acid gpr120 modulators SG11201506799RA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361782339P 2013-03-14 2013-03-14
US14/205,421 US8962660B2 (en) 2013-03-14 2014-03-12 Oxabicyclo [2.2.2] acid GPR120 modulators
PCT/US2014/025287 WO2014151247A1 (en) 2013-03-14 2014-03-13 Oxabicyclo [2.2.2] acid gpr120 modulators

Publications (1)

Publication Number Publication Date
SG11201506799RA true SG11201506799RA (en) 2015-09-29

Family

ID=51529985

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201506799RA SG11201506799RA (en) 2013-03-14 2014-03-13 Oxabicyclo [2.2.2] acid gpr120 modulators

Country Status (13)

Country Link
US (1) US8962660B2 (en)
EP (1) EP2970327B1 (en)
JP (1) JP2016512556A (en)
KR (1) KR20150128860A (en)
CN (1) CN105189516B (en)
AU (1) AU2014235172B2 (en)
BR (1) BR112015021596A2 (en)
CA (1) CA2905448A1 (en)
EA (1) EA201591805A1 (en)
IL (1) IL241323B (en)
MX (1) MX362383B (en)
SG (1) SG11201506799RA (en)
WO (1) WO2014151247A1 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20150724A1 (en) * 2012-04-27 2015-05-17 Novartis Ag BRIDGE HEAD CYCLIC ETHER DGAT1 INHIBITORS
TW201427971A (en) * 2012-11-16 2014-07-16 必治妥美雅史谷比公司 Dihydropyrazole GPR40 modulators
JP2016516708A (en) 2013-03-14 2016-06-09 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ GPR120 modulator of bicyclo [2.2.2] acid
EP2970092B1 (en) 2013-03-14 2016-12-14 Bristol-Myers Squibb Company Bicyclo [2.2.1]acid gpr120 modulators
EP2860177A3 (en) * 2013-09-20 2015-06-10 Bayer Intellectual Property GmbH Synthesis of functionalized arenes
WO2016040223A1 (en) 2014-09-09 2016-03-17 Bristol-Myers Squibb Company Cyclobutane containing carboxylic acid gpr120 modulators
EP3191454B1 (en) 2014-09-09 2018-10-24 Bristol-Myers Squibb Company Cyclopropanecarboxylic acid gpr120 modulators
ES2760266T3 (en) 2014-09-09 2020-05-13 Bristol Myers Squibb Co Phenyl- (aza) cycloalkyl carboxylic acid GPR120 modulators
KR20170031400A (en) 2015-09-11 2017-03-21 주식회사 만도 Electric brake system
WO2017161145A1 (en) 2016-03-18 2017-09-21 Bristol-Myers Squibb Company Triazolopyridine inhibitors of myeloperoxidase and/or epx
KR102537985B1 (en) 2016-09-12 2023-05-30 인테그랄 헬스 인코퍼레이티드 Monocyclic Compounds Useful as GPR120 Modulators
CN108456213B (en) * 2017-02-22 2021-01-15 浙江九洲药业股份有限公司 Preparation method of 3-fluoro-4-hydroxycyclohexane carboxylate
CN111868035A (en) 2018-03-15 2020-10-30 阿克萨姆股份公司 Substituted pyrazole FFA4/GPR120 receptor agonists
US20210317131A1 (en) 2018-09-18 2021-10-14 Bristol-Myers Squibb Company Oxabicyclo acids as lpa antagonists
CN111233889B (en) * 2020-03-02 2021-09-14 北方民族大学 Preparation method of thieno [3,4-b ] -1, 4-dioxin-2-methanol derivative
CN113912619B (en) * 2021-11-26 2022-12-06 沈阳药科大学 Sesquiterpene compound extracted and separated from schisandra chinensis and method and application thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5614492A (en) 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
PL206890B1 (en) 1999-11-12 2010-10-29 Biogen Idec Ma Polycycloalkylpurines as adenosine receptor antagonists
WO2005051890A1 (en) 2003-11-19 2005-06-09 Smithkline Beecham Corporation Aminophenylcyclopropyl carboxylic acids and derivatives as agonists to gpr40
MY151167A (en) * 2005-04-15 2014-04-30 Eisai R&D Man Co Ltd Benzimidazole compound
JP5084503B2 (en) 2005-07-29 2012-11-28 武田薬品工業株式会社 Cyclopropanecarboxylic acid compound
CL2008003407A1 (en) 2007-11-16 2010-01-11 Boehringer Ingelheim Int Substituted heterobicyclo aryl- and heteroarylcarbonyl derivative compounds; pharmaceutical composition; preparation procedure; and its use in the treatment and / or prevention of metabolic disorders, mediated by the inhibition of the enzyme hsd-1.
JP5662803B2 (en) 2007-12-20 2015-02-04 アストラゼネカ アクチボラグ Carbamoyl compounds 190 as DGAT1 inhibitors
ES2466695T3 (en) 2008-10-30 2014-06-11 Biogen Idec Ma Inc. Bicyclic aryl sphingosine 1-phosphate analogs
KR20120104534A (en) 2009-10-06 2012-09-21 브리스톨-마이어스 스큅 컴퍼니 Pyrrolidine gpr40 modulators
WO2011075607A1 (en) 2009-12-18 2011-06-23 Intermune, Inc. Novel inhibitors of hepatitis c virus replication
WO2012124744A1 (en) 2011-03-14 2012-09-20 大正製薬株式会社 Nitrogen-containing condensed heterocyclic compound
PE20150724A1 (en) 2012-04-27 2015-05-17 Novartis Ag BRIDGE HEAD CYCLIC ETHER DGAT1 INHIBITORS
US9120798B2 (en) 2012-08-01 2015-09-01 Bristol-Myers Squibb Company Amino-heteroaryl 7-hydroxy-spiropiperidine indolinyl antagonists of P2Y1 receptor
BR112015010649A2 (en) 2012-11-16 2017-07-11 Bristol Myers Squibb Co pyrrolidine-based gpr40 modulators
AR104762A1 (en) 2012-11-16 2017-08-16 Bristol Myers Squibb Co GPR40 DIHYDROPIRAZOL MODULATORS

Also Published As

Publication number Publication date
CA2905448A1 (en) 2014-09-25
CN105189516B (en) 2017-08-15
US20140275173A1 (en) 2014-09-18
EP2970327B1 (en) 2017-05-03
JP2016512556A (en) 2016-04-28
CN105189516A (en) 2015-12-23
BR112015021596A2 (en) 2017-07-18
MX2015011913A (en) 2015-12-09
AU2014235172B2 (en) 2018-04-26
EP2970327A1 (en) 2016-01-20
KR20150128860A (en) 2015-11-18
EA201591805A1 (en) 2016-01-29
IL241323A0 (en) 2015-11-30
MX362383B (en) 2019-01-15
WO2014151247A1 (en) 2014-09-25
AU2014235172A1 (en) 2015-11-05
IL241323B (en) 2018-10-31
US8962660B2 (en) 2015-02-24

Similar Documents

Publication Publication Date Title
IL241323B (en) Oxabicyclo [2.2.2] acid gpr120 modulators
EP2993544A4 (en) Autonomous moving body
EP2969630A4 (en) Axle assembly
IL241318A0 (en) Bicyclo [2.2.2] acid gpr120 modulators
EP3032248A4 (en) Biosensor
EP3048930A4 (en) Gear track system
EP3036004A4 (en) Dendrimer-resveratrol complex
IL241245A (en) Bicyclo [2.2.1] acid gpr120 modulators
EP3057708A4 (en) Improved thermocycler
EP3055644A4 (en) Wavelength-encoded tomography
EP3088520A4 (en) IMPROVED ß-FRUCTOFURANOSIDASE
PL2994325T3 (en) Axle connection
EP2894773A4 (en) Resolver
EP2997013A4 (en) Pyridine- or pyrazine-containing compounds
EP3023776A4 (en) Anion sensor
GB2521592B (en) Axles
AU2013100858A4 (en) Steerin Wheelz
AU2013904222A0 (en) Type 24 Vehicles
AU2013903799A0 (en) Type 23 Vehicles
AU2013902967A0 (en) Type 23 Vehicles
AU2013902046A0 (en) Type 23 Vehicles
AU2014276609A1 (en) Agitator assembly
AU2013904815A0 (en) Structured globules
AU2013903776A0 (en) The mungrill
AU2013902343A0 (en) Fertilizer